{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:37:47Z","timestamp":1792813067841,"version":"4.5.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,11]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Posttransplantation cyclophosphamide is effective as sole GVHD prophylaxis for myeloablative HLA-matched\u2013related or \u2013unrelated BMT. Despite low chronic GVHD with PTCy, relapse and survival are comparable with outcomes reported using other GVHD prophylactic approaches.<\/jats:p>","DOI":"10.1182\/blood-2014-07-587477","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T07:05:41Z","timestamp":1413356741000},"page":"3817-3827","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":188,"title":["Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS"],"prefix":"10.1182","volume":"124","author":[{"given":"Christopher G.","family":"Kanakry","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Kanakry","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette L.","family":"Kasamon","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Matsui","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Borrello","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Powell","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith W.","family":"Pratz","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Showel","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"McDevitt","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Rosner","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2019111821435771600_B1","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","article-title":"Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.","volume":"304","author":"Weiden","year":"1981","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111821435771600_B2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation.","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"11","key":"2019111821435771600_B3","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.bbmt.2012.06.014","article-title":"Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.","volume":"18","author":"Weisdorf","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2019111821435771600_B4","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111821435771600_B5","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"issue":"16","key":"2019111821435771600_B6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors.","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111821435771600_B7","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","article-title":"Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.","volume":"117","author":"Soci\u00e9","year":"2011","journal-title":"Blood"},{"issue":"9487","key":"2019111821435771600_B8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(05)66996-6","article-title":"Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.","volume":"366","author":"Wagner","year":"2005","journal-title":"Lancet"},{"issue":"25","key":"2019111821435771600_B9","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","article-title":"Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.","volume":"117","author":"Soiffer","year":"2011","journal-title":"Blood"},{"issue":"1-3","key":"2019111821435771600_B10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol Res"},{"issue":"6","key":"2019111821435771600_B11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 2","key":"2019111821435771600_B12","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.4081\/pr.2011.s2.e15","article-title":"Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide.","volume":"3","author":"Munchel","year":"2011","journal-title":"Pediatr Rep"},{"issue":"16","key":"2019111821435771600_B13","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111821435771600_B14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"key":"2019111821435771600_B15","author":"Kanakry"},{"issue":"31","key":"2019111821435771600_B16","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111821435771600_B17","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111821435771600_B18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"12","key":"2019111821435771600_B19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111821435771600_B20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2009-03-212290","article-title":"Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.","volume":"114","author":"Alousi","year":"2009","journal-title":"Blood"},{"key":"2019111821435771600_B21","author":"Bola\u00f1os-Meade"},{"issue":"24","key":"2019111821435771600_B22","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111821435771600_B23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.","volume":"24","author":"Br\u00fcggemann","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019111821435771600_B24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"2019111821435771600_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-Estimation from Incomplete Observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111821435771600_B26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2019111821435771600_B27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"8","key":"2019111821435771600_B28","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111821435771600_B29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111821435771600_B30","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study.","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111821435771600_B31","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"29","key":"2019111821435771600_B32","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111821435771600_B33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbmt.2011.07.024","article-title":"Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.","volume":"18","author":"Armand","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111821435771600_B34","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","article-title":"Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.","volume":"17","author":"Devine","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2019111821435771600_B35","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2012.41.7071","article-title":"Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.","volume":"30","author":"Pasquini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111821435771600_B36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.4049\/jimmunol.145.5.1303","article-title":"Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion.","volume":"145","author":"Eto","year":"1990","journal-title":"J Immunol"},{"issue":"6","key":"2019111821435771600_B37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbmt.2007.01.079","article-title":"Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.","volume":"13","author":"Armand","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111821435771600_B38","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood-2009-07-231068","article-title":"Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies.","volume":"115","author":"Barker","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111821435771600_B39","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1182\/blood-2002-01-0339","article-title":"Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation.","volume":"100","author":"Dominietto","year":"2002","journal-title":"Blood"},{"issue":"21","key":"2019111821435771600_B40","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2002.11.058","article-title":"Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey.","volume":"20","author":"Rocha","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111821435771600_B41","first-page":"3323","article-title":"Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.","volume":"95","author":"Barrett","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2019111821435771600_B42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2010.06.011","article-title":"Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation.","volume":"17","author":"Peffault de Latour","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111821435771600_B43","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.V99.6.1943","article-title":"Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.","volume":"99","author":"Castro-Malaspina","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111821435771600_B44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/pbc.22677","article-title":"Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation.","volume":"56","author":"Lin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2019111821435771600_B45","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy.","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"issue":"8530","key":"2019111821435771600_B46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0140-6736(87)90166-8","article-title":"Graft-versus-leukaemia activity associated with cytomegalovirus antibody positive bone marrow donors in acute myeloid leukaemia.","volume":"1","author":"Jacobsen","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"2019111821435771600_B47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1600-0609.2005.00625.x","article-title":"Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.","volume":"76","author":"Nachbaur","year":"2006","journal-title":"Eur J Haematol"},{"issue":"13","key":"2019111821435771600_B48","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2002-10-3263","article-title":"Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis.","volume":"102","author":"Ljungman","year":"2003","journal-title":"Blood"},{"issue":"19","key":"2019111821435771600_B49","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111821435771600_B50","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111821435771600_B51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/17474086.2014.857596","article-title":"Allogeneic stem cell transplantation and targeted therapy for FLT3\/ITD+ acute myeloid leukemia: an update.","volume":"7","author":"Hu","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2019111821435771600_B52","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bbmt.2013.02.018","article-title":"Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111821435771600_B53","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/25\/3817\/1465180\/3817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/25\/3817\/1465180\/3817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T08:15:07Z","timestamp":1689581707000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/25\/3817\/33618\/Singleagent-GVHD-prophylaxis-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,11]]},"references-count":53,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2014,12,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-07-587477","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,11]]}}}